What are the recent trends in market size and growth for the biliary tract cancer market?
The biliary tract cancer market size has grown strongly in recent years. It will grow from $0.67 billion in 2024 to $0.72 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to the increasing incidence of biliary tract cancer, growing demand for effective therapies, a rise in risk factors such as obesity, an aging population, and increasing investment in research and development.
The biliary tract cancer market size is expected to see strong growth in the next few years. It will grow to $0.95 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to lifestyle changes, growing awareness, early detection initiatives, favorable reimbursement policies, and growing government policies. Major trends in the forecast period include technological advancements in diagnosis and treatment, adoption of immunotherapy, rising demand for precision medicine, evolving treatment approaches, and development in biomarker-based therapies.
Get Your Free Sample of The Global Biliary Tract Cancer Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21114&type=smp
How have varous drivers impacted the growth of the biliary tract cancer market?
The increasing prevalence of obesity is expected to propel the growth of the biliary tract cancer market going forward. Obesity is a chronic medical condition characterized by an excessive accumulation of body fat that can adversely affect health. The obesity prevalence increase is due to factors including physical inactivity, psychological factors, age, and genetic and biological factors. Obesity triggers chronic inflammation, insulin resistance, and excess bile acid secretion, leading to DNA damage and tumor growth. It also disrupts hormones and metabolism, fostering a cancer-prone environment in the biliary tract. For instance, in September 2023, according to the Centers for Disease Control and Prevention, a US-based government agency, in 2022, the number of states with an adult obesity rate of 35% or higher has risen to 22, up from 19 in 2021. Therefore, the increasing prevalence of obesity is driving the growth of the biliary tract cancer market.
What are the primary segments of the biliary tract cancer market?
The biliary tract cancer market covered in this report is segmented –
1) By Cancer Type: Intrahepatic Bile Duct Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
2) By Treatment: Chemotherapy, Targeted Therapy, Immunotherapy
3) By End-User: Hospitals, Specialty Cancer Centres, Ambulatory Surgical Centres, Other End-Users
Subsegments:
1) By Intrahepatic Bile Duct Cancer: Peripheral Intrahepatic Bile Duct Cancer, Hilar Intrahepatic Bile Duct Cancer
2) By Extrahepatic Bile Duct Cancer: Perihilar Bile Duct Cancer, Distal Bile Duct Cancer
3) By Gallbladder Cancer: Localized Gallbladder Cancer, Advanced Gallbladder Cancer
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/biliary-tract-cancer-global-market-report
Which firms are leading the biliary tract cancer market?
Major companies operating in the biliary tract cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca Plc, Eli Lily and Company, Boehringer Ingelheim International GmbH, Eisai Co. Ltd., Servier Pharmaceuticals, Jazz Pharmaceuticals plc, Incyte Corporation, BeiGene LTD., Zymeworks, Basilea Pharmaceutica Ltd., Taiho Oncology Inc., RenovoRx Inc., TransThera Sciences Inc., QED Therapeutics Inc., Helsinn Group
How will industry trends affect the trajectory of the biliary tract cancer market?
Major companies operating in the biliary tract cancer market are focusing on developing advanced combination treatment to enhance efficacy and improve patient outcomes. Combination therapy refers to the use of two or more medications or treatment modalities simultaneously to treat a single disease. For instance, in November 2023, Merck & Co. Inc., a US-based pharmaceutical company, received the U.S. Food and Drug Administration (FDA) approval for KEYTRUDA (pembrolizumab) in combination with gemcitabine and cisplatin for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer (BTC). This decision was based on the results from the Phase 3 KEYNOTE-966 trial, which demonstrated a statistically significant improvement in overall survival, reducing the risk of death by 17% compared to chemotherapy alone. The median overall survival for patients receiving the combination therapy was 12.7 months, compared to 10.9 months for those receiving only chemotherapy, marking this as a significant advancement in treatment options for this challenging cancer type.
Which geographic trends are shaping the biliary tract cancer market, and which region has the highest market share?
North America was the largest region in the biliary tract cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biliary tract cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Biliary Tract Cancer Market Report 2025 Offer?
The biliary tract cancer market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Biliary tract cancer (BTC), also known as cholangiocarcinoma, is a rare malignancy that arises in the bile ducts, gallbladder, or ampulla of Vater. This cancer disrupts bile flow, which plays a crucial role in digestion and waste elimination. Research and treatment efforts of biliary tract cancer focus on early detection, advancing therapeutic options, and improving survival rates for affected patients.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21114
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
